Carfilzomib consolidation with cyclophosphamide and dexamethasone conferred noninferior results compared to upfront autologous stem cell transplantation in newly diagnosed, transplant-eligible patients with multiple myeloma.
Recent Content
- FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy
- European Commission Approves Cilta-Cel for Relapsed/Refractory Multiple Myeloma
- Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma
- Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial
- Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
- Elotuzumab Efficacy May Suffer if Given After Daratumumab in Multiple Myeloma
- Practical Considerations of T-Cell Engagers in the Management of Relapsed/Refractory Multiple Myeloma
- Cilta-Cel Allows for Treatment-Free Period in Early R/R Multiple Myeloma
- Dr Jagannath on the Mechanism of Action of Linvoseltamab in R/R Multiple Myeloma
- Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma